Related Experiment Videos
A guide to device selection: cardiac resynchronization therapy alone or in combination with an implantable
1The Care Group, LLC, Indiana Heart Institute, St. Vincent Hospital, Indianapolis, IN, USA.
Insights
Sudden cardiac death (SCD) prevention strategies have evolved. While antiarrhythmic drugs to suppress premature ventricular complexes (PVCs) proved ineffective, implantable cardioverter defibrillators (ICDs) are now the most significant therapy for preventing SCD.
Area of Science:
- Cardiology
- Clinical Medicine
- Public Health
Background:
- Sudden cardiac death (SCD) incidence is reportedly increasing in the US.
- Effective risk identification and prevention methods are crucial for reducing SCD.
- Current risk stratification and treatment approaches stem from key research milestones.
Purpose of the Study:
- To review research milestones in SCD risk stratification and treatment.
- To evaluate the efficacy of past and current interventions for high-risk patients.
- To provide an updated perspective on preventing sudden cardiac death.
Main Methods:
- Review of historical and contemporary clinical trial data.
- Analysis of antiarrhythmic drug trials for premature ventricular complex (PVC) suppression.
- Evaluation of implantable cardioverter defibrillator (ICD) efficacy studies.
- Assessment of amiodarone's role in specific patient populations.
Main Results:
- Early trials of antiarrhythmic drugs for PVC suppression showed negative survival outcomes.
- Amiodarone is not recommended for primary SCD prevention or survival benefit in heart failure patients.
- Implantable cardioverter defibrillators (ICDs) are the most effective therapy for ventricular arrhythmias and SCD prevention.
- ICDs are recommended for most patients receiving cardiac resynchronization therapy.
Conclusions:
- Past strategies targeting PVC suppression have failed to reduce mortality.
- Current evidence strongly supports ICDs as the primary therapy for preventing sudden cardiac death.
- Integrating ICDs with cardiac resynchronization therapy enhances patient outcomes.
Abstract:
The most recent estimates show an apparent increase in sudden cardiac death (SCD) in the United States. A major reduction in SCD will depend on developing effective methods to identify and prevent risk factors for SCD. This article reviews the research milestones that have resulted in our current approach to risk stratification and treatment of patients at high risk for SCD. One of the earliest attempts to prevent SCD involved suppression of premature ventricular complexes (PVCs) in high-risk patients, but trials using a variety of antiarrhythmic drugs with the aim of suppressing PVCs and reducing mortality demonstrated negative survival results. In the case of amiodarone, clinical trial data to date suggest that it should not be used for primary prevention of SCD or to prolong survival in patients with congestive heart failure secondary to coronary artery disease. The implantable cardioverter defibrillator (ICD) has been demonstrated in multiple studies to be the most significant therapy for life-threatening ventricular arrhythmias and for primary and secondary prevention of SCD. It is recommended that the majority of patients who receive cardiac resynchronization therapy should have an ICD unit implanted in order to include defibrillator therapy.